Carnegie acted as joint financial adviser to the major shareholders of Mabtech in the sale to EQT. IK Partners and Mérieux Equity Partners have signed an agreement to sell their respective stakes in Mabtech, a Swedish biotech company developing immunoassays for life science research, to EQT.
Mabtech is a global manufacturer of high-quality antibodies, kits and readers used to study immune responses, including those in cancer immunotherapies and infectious diseases. Its products and services help to advance biomedical research and develop vaccines, cell and gene therapies.